|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 112.90 SEK | +0.36% |
|
+6.91% | +6.31% |
| Capitalization | 11.38B 1.24B 1.06B 988M 921M 1.72B 112B 1.85B 4.47B 53.49B 4.65B 4.56B 196B | P/E ratio 2025 * |
36.5x | P/E ratio 2026 * | 27.4x |
|---|---|---|---|---|---|
| Enterprise value | 10.56B 1.15B 986M 917M 855M 1.6B 104B 1.71B 4.15B 49.65B 4.32B 4.23B 182B | EV / Sales 2025 * |
7.09x | EV / Sales 2026 * | 6.52x |
| Free-Float |
87.96% | Yield 2025 * |
4.62% | Yield 2026 * | 4.62% |
Last Transcript: BioGaia AB
| 1 day | +0.62% | ||
| 1 week | +6.91% | ||
| Current month | +6.31% | ||
| 1 month | +15.50% | ||
| 3 months | +6.31% | ||
| 6 months | +6.21% | ||
| Current year | +6.31% |
| 1 week | 105.1 |  | 114.2 |
| 1 month | 97.4 | | 114.2 |
| Current year | 104.8 | | 114.2 |
| 1 year | 93.2 | | 139.7 |
| 3 years | 87.95 | | 139.7 |
| 5 years | 68.88 | | 139.7 |
| 10 years | 39.4 | | 139.7 |
| Manager | Title | Age | Since |
|---|---|---|---|
Theresa Agnew
CEO | Chief Executive Officer | 60 | 2023-09-29 |
| Director of Finance/CFO | 59 | 2019-11-04 | |
Ludvig Milesson
COO | Chief Operating Officer | 49 | 2020-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
David Dangoor
CHM | Chairman | 77 | 2002-12-31 |
| Chairman | 76 | 2018-04-24 | |
Barbro Fridén
BRD | Director/Board Member | 70 | 2023-05-04 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.36% | +6.91% | +1.53% | +25.46% | 1.24B | |
| -3.52% | +1.47% | +8.03% | +8.38% | 81.73B | |
| -0.37% | +87.80% | +87.80% | +87.80% | 59.54B | |
| -1.14% | +7.24% | +31.71% | +223.03% | 56.31B | |
| +0.46% | +1.83% | -38.58% | -37.03% | 56.11B | |
| -1.81% | +5.67% | +22.88% | -35.94% | 27.52B | |
| -0.68% | +4.18% | +46.52% | +31.81% | 20.98B | |
| +0.17% | +7.00% | +164.25% | +125.31% | 19.71B | |
| +6.79% | +11.82% | +65.11% | +1,364.18% | 18.72B | |
| -2.27% | +1.20% | +120.28% | +752.06% | 14.89B | |
| Average | -0.14% | +6.15% | +50.95% | +254.51% | 35.67B | |
| Weighted average by Cap. | -0.80% | +5.73% | +37.45% | +155.02% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 1.49B 163M 139M 129M 121M 225M 14.65B 242M 586M 7.01B 610M 597M 25.7B | 1.64B 179M 153M 142M 133M 248M 16.11B 266M 645M 7.71B 670M 657M 28.26B |
| Net income | 311M 33.9M 29.03M 27M 25.17M 47.03M 3.06B 50.44M 122M 1.46B 127M 125M 5.36B | 415M 45.24M 38.74M 36.03M 33.59M 62.76M 4.08B 67.31M 163M 1.95B 170M 166M 7.15B |
| Net Debt | -817M -89.06M -76.26M -70.92M -66.12M -124M -8.03B -133M -321M -3.84B -334M -327M -14.08B | -687M -74.89M -64.13M -59.64M -55.6M -104M -6.75B -111M -270M -3.23B -281M -275M -11.84B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-01-12 | 112.90 kr | +0.36% | 367,183 |
| 26-01-09 | 112.50 kr | +3.12% | 300,579 |
| 26-01-08 | 109.10 kr | +2.63% | 279,046 |
| 26-01-07 | 106.30 kr | +0.66% | 198,166 |
| 26-01-05 | 105.60 kr | +0.57% | 99,914 |
Delayed Quote Nasdaq Stockholm, January 12, 2026 at 12:00 pm EST
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- BIOG B Stock
Select your edition
All financial news and data tailored to specific country editions
